BioCryst Pharmaceuticals, Inc. (BCRX)
USD 6.47
(-4.71%)
USD 6.47
(-4.71%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -103.7 Million USD | 30.13% |
| 2022 | -148.43 Million USD | 16.48% |
| 2021 | -177.72 Million USD | -1.7% |
| 2020 | -174.75 Million USD | -75.71% |
| 2019 | -99.45 Million USD | -5.56% |
| 2018 | -94.22 Million USD | -64.11% |
| 2017 | -57.41 Million USD | -18.11% |
| 2016 | -48.6 Million USD | -23.23% |
| 2015 | -39.44 Million USD | 13.82% |
| 2014 | -45.77 Million USD | -49.01% |
| 2013 | -30.71 Million USD | 9.36% |
| 2012 | -33.88 Million USD | 31.66% |
| 2011 | -49.58 Million USD | -49.19% |
| 2010 | -33.23 Million USD | -141.93% |
| 2009 | -13.73 Million USD | 49.43% |
| 2008 | -27.16 Million USD | 15.85% |
| 2007 | -32.28 Million USD | 31.29% |
| 2006 | -46.97 Million USD | -72.87% |
| 2005 | -27.17 Million USD | -24.94% |
| 2004 | -21.75 Million USD | -71.27% |
| 2003 | -12.7 Million USD | 23.28% |
| 2002 | -16.55 Million USD | -232.06% |
| 2001 | -4.98 Million USD | 49.29% |
| 2000 | -9.83 Million USD | -21.38% |
| 1999 | -8.1 Million USD | -35.0% |
| 1998 | -6 Million USD | 51.22% |
| 1997 | -12.3 Million USD | -61.84% |
| 1996 | -7.6 Million USD | 16.48% |
| 1995 | -9.1 Million USD | -33.82% |
| 1994 | -6.8 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -14.36 Million USD | 66.34% |
| 2024 Q2 | 8.76 Million USD | 161.01% |
| 2024 Q3 | 7.69 Million USD | -12.2% |
| 2023 Q3 | -11.92 Million USD | 42.42% |
| 2023 Q1 | -28.41 Million USD | 38.64% |
| 2023 Q2 | -20.7 Million USD | 27.14% |
| 2023 FY | -103.7 Million USD | 30.13% |
| 2023 Q4 | -42.67 Million USD | -257.94% |
| 2022 FY | -148.43 Million USD | 16.48% |
| 2022 Q1 | -49.95 Million USD | 4.25% |
| 2022 Q2 | -34.72 Million USD | 30.5% |
| 2022 Q3 | -17.44 Million USD | 49.76% |
| 2022 Q4 | -46.31 Million USD | -165.47% |
| 2021 Q4 | -52.17 Million USD | -17.03% |
| 2021 FY | -177.72 Million USD | -1.7% |
| 2021 Q1 | -51.37 Million USD | 1.96% |
| 2021 Q2 | -29.58 Million USD | 42.42% |
| 2021 Q3 | -44.58 Million USD | -50.71% |
| 2020 FY | -174.75 Million USD | -75.71% |
| 2020 Q1 | -40.97 Million USD | -37494.5% |
| 2020 Q2 | -38.51 Million USD | 6.02% |
| 2020 Q3 | -42.86 Million USD | -11.31% |
| 2020 Q4 | -52.4 Million USD | -22.26% |
| 2019 Q4 | -109 Thousand USD | 99.69% |
| 2019 Q3 | -35.09 Million USD | -0.52% |
| 2019 Q1 | -29.33 Million USD | -16.1% |
| 2019 Q2 | -34.91 Million USD | -19.05% |
| 2019 FY | -99.45 Million USD | -5.56% |
| 2018 Q2 | -18.25 Million USD | 17.84% |
| 2018 FY | -94.22 Million USD | -64.11% |
| 2018 Q1 | -22.21 Million USD | -24.37% |
| 2018 Q3 | -28.49 Million USD | -56.12% |
| 2018 Q4 | -25.26 Million USD | 11.34% |
| 2017 Q3 | -13.34 Million USD | 13.97% |
| 2017 FY | -57.41 Million USD | -18.11% |
| 2017 Q1 | -10.68 Million USD | -30.5% |
| 2017 Q4 | -17.86 Million USD | -33.8% |
| 2017 Q2 | -15.51 Million USD | -45.21% |
| 2016 Q1 | -19.04 Million USD | -10.78% |
| 2016 Q4 | -8.18 Million USD | 11.39% |
| 2016 FY | -48.6 Million USD | -23.23% |
| 2016 Q3 | -9.24 Million USD | 23.82% |
| 2016 Q2 | -12.13 Million USD | 36.32% |
| 2015 Q4 | -17.19 Million USD | -30.63% |
| 2015 Q2 | 5.34 Million USD | 137.02% |
| 2015 Q1 | -14.43 Million USD | 4.79% |
| 2015 FY | -39.44 Million USD | 13.82% |
| 2015 Q3 | -13.16 Million USD | -346.39% |
| 2014 FY | -45.77 Million USD | -49.01% |
| 2014 Q4 | -15.15 Million USD | -30.54% |
| 2014 Q3 | -11.61 Million USD | 0.08% |
| 2014 Q2 | -11.61 Million USD | -57.31% |
| 2014 Q1 | -7.38 Million USD | -16.61% |
| 2013 Q1 | -5.31 Million USD | 50.29% |
| 2013 Q3 | -6.92 Million USD | 42.97% |
| 2013 Q4 | -6.33 Million USD | 8.53% |
| 2013 FY | -30.71 Million USD | 9.36% |
| 2013 Q2 | -12.14 Million USD | -128.4% |
| 2012 FY | -33.88 Million USD | 31.66% |
| 2012 Q2 | -10.17 Million USD | -103.48% |
| 2012 Q3 | -8.01 Million USD | 21.23% |
| 2012 Q4 | -10.69 Million USD | -33.42% |
| 2012 Q1 | -5 Million USD | 54.71% |
| 2011 Q1 | -11.49 Million USD | -11.56% |
| 2011 Q2 | -14.24 Million USD | -23.86% |
| 2011 Q3 | -12.8 Million USD | 10.1% |
| 2011 Q4 | -11.04 Million USD | 13.77% |
| 2011 FY | -49.58 Million USD | -49.19% |
| 2010 Q4 | -10.3 Million USD | 6.21% |
| 2010 FY | -33.23 Million USD | -141.93% |
| 2010 Q3 | -10.99 Million USD | -6.39% |
| 2010 Q1 | -2.72 Million USD | -118.09% |
| 2010 Q2 | -10.33 Million USD | -278.53% |
| 2009 Q3 | -10.69 Million USD | -22.41% |
| 2009 Q1 | -9.38 Million USD | -195.74% |
| 2009 FY | -13.73 Million USD | 49.43% |
| 2009 Q4 | 15.08 Million USD | 241.03% |
| 2009 Q2 | -8.73 Million USD | 6.9% |
| 2008 FY | -27.16 Million USD | 15.85% |
| 2008 Q4 | 9.8 Million USD | 202.42% |
| 2008 Q3 | -9.57 Million USD | 28.45% |
| 2008 Q2 | -13.38 Million USD | 4.54% |
| 2008 Q1 | -14.01 Million USD | -308.86% |
| 2007 Q3 | -11.86 Million USD | -56.45% |
| 2007 Q2 | -7.58 Million USD | -705.91% |
| 2007 Q1 | -940.8 Thousand USD | 91.24% |
| 2007 FY | -32.28 Million USD | 31.29% |
| 2007 Q4 | -3.42 Million USD | 71.1% |
| 2006 Q2 | -11.01 Million USD | -25.65% |
| 2006 Q1 | -8.76 Million USD | -17.08% |
| 2006 FY | -46.97 Million USD | -72.87% |
| 2006 Q4 | -10.73 Million USD | 34.76% |
| 2006 Q3 | -16.45 Million USD | -49.41% |
| 2005 Q4 | -7.48 Million USD | 5.54% |
| 2005 Q3 | -7.92 Million USD | -33.63% |
| 2005 Q2 | -5.93 Million USD | -1.75% |
| 2005 FY | -27.17 Million USD | -24.94% |
| 2005 Q1 | -5.83 Million USD | 1.8% |
| 2004 Q3 | -5.29 Million USD | -4.73% |
| 2004 Q2 | -5.05 Million USD | 7.41% |
| 2004 Q4 | -5.93 Million USD | -12.1% |
| 2004 FY | -21.75 Million USD | -71.27% |
| 2004 Q1 | -5.46 Million USD | -68.06% |
| 2003 Q3 | -3.4 Million USD | 3.1% |
| 2003 Q4 | -3.25 Million USD | 4.66% |
| 2003 Q2 | -3.51 Million USD | -26.18% |
| 2003 Q1 | -2.78 Million USD | -1.91% |
| 2003 FY | -12.7 Million USD | 23.28% |
| 2002 FY | -16.55 Million USD | -232.06% |
| 2002 Q4 | -2.73 Million USD | 19.89% |
| 2002 Q3 | -3.41 Million USD | 28.66% |
| 2002 Q2 | -4.78 Million USD | 14.76% |
| 2002 Q1 | -5.61 Million USD | -115.63% |
| 2001 Q3 | -119 Thousand USD | -316.36% |
| 2001 FY | -4.98 Million USD | 49.29% |
| 2001 Q1 | -2.56 Million USD | 50.95% |
| 2001 Q2 | 55 Thousand USD | 102.14% |
| 2001 Q4 | -2.6 Million USD | -2088.67% |
| 2000 Q3 | -2.68 Million USD | 13.24% |
| 2000 FY | -9.83 Million USD | -21.38% |
| 2000 Q4 | -5.23 Million USD | -94.68% |
| 2000 Q2 | -3.09 Million USD | -266.57% |
| 2000 Q1 | 1.85 Million USD | 177.47% |
| 1999 Q4 | -2.4 Million USD | 4.0% |
| 1999 FY | -8.1 Million USD | -35.0% |
| 1999 Q3 | -2.5 Million USD | -400.0% |
| 1999 Q2 | -500 Thousand USD | 82.14% |
| 1999 Q1 | -2.8 Million USD | -55.56% |
| 1998 Q1 | -3.2 Million USD | 5.88% |
| 1998 Q4 | -1.8 Million USD | -175.0% |
| 1998 Q3 | 2.4 Million USD | 175.0% |
| 1998 Q2 | -3.2 Million USD | 0.0% |
| 1998 FY | -6 Million USD | 51.22% |
| 1997 Q1 | -3.1 Million USD | -47.62% |
| 1997 FY | -12.3 Million USD | -61.84% |
| 1997 Q4 | -3.4 Million USD | -21.43% |
| 1997 Q3 | -2.8 Million USD | -33.33% |
| 1997 Q2 | -2.1 Million USD | 32.26% |
| 1996 Q2 | -1.3 Million USD | 31.58% |
| 1996 Q1 | -1.9 Million USD | 17.39% |
| 1996 FY | -7.6 Million USD | 16.48% |
| 1996 Q4 | -2.1 Million USD | 12.5% |
| 1996 Q3 | -2.4 Million USD | -84.62% |
| 1995 Q1 | -2.9 Million USD | -52.63% |
| 1995 FY | -9.1 Million USD | -33.82% |
| 1995 Q3 | -2.1 Million USD | -23.53% |
| 1995 Q4 | -2.3 Million USD | -9.52% |
| 1995 Q2 | -1.7 Million USD | 41.38% |
| 1994 Q1 | -1.5 Million USD | 0.0% |
| 1994 Q3 | -1.7 Million USD | 10.53% |
| 1994 Q4 | -1.9 Million USD | -11.76% |
| 1994 FY | -6.8 Million USD | 0.0% |
| 1994 Q2 | -1.9 Million USD | -26.67% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Akebia Therapeutics, Inc. | -46.25 Million USD | -124.207% |
| Jaguar Health, Inc. | -34.29 Million USD | -202.438% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 38.974% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -82.718% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 63.247% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 968.439% |
| ContextLogic Inc. | -328 Million USD | 68.381% |
| MiMedx Group, Inc. | 37.11 Million USD | 379.419% |
| MEI Pharma, Inc. | 14.54 Million USD | 813.169% |
| AlloVir, Inc. | -181.33 Million USD | 42.807% |
| Novavax, Inc. | -566.51 Million USD | 81.693% |
| Aptorum Group Limited | -10.52 Million USD | -885.515% |
| Ardelyx, Inc. | -63.27 Million USD | -63.899% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 49.411% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -3668.735% |
| Vaxcyte, Inc. | -468.04 Million USD | 77.842% |
| Precigen, Inc. | -88.92 Million USD | -16.628% |
| Pharming Group N.V. | -4.87 Million USD | -2025.383% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 38.015% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | -248.531% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | -406.12% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 55.981% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | -434.073% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -326.67% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -326.67% |
| Bicycle Therapeutics plc | -189.94 Million USD | 45.401% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 62.151% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | -253.895% |
| Acelyrin, Inc. | -422.06 Million USD | 75.428% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | -173.863% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | -179.811% |
| Senti Biosciences, Inc. | -92.72 Million USD | -11.843% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 9.64% |
| AbCellera Biologics Inc. | -237.2 Million USD | 56.279% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | -202.65% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 39.628% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -3179.855% |
| Chimerix, Inc. | -93.06 Million USD | -11.437% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | -214.07% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -491.305% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -130.069% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | -104.582% |
| Elevation Oncology, Inc. | -45.44 Million USD | -128.208% |
| Alkermes plc | 414.12 Million USD | 125.043% |
| Fortress Biotech, Inc. | -142.34 Million USD | 27.141% |
| Fortress Biotech, Inc. | -142.34 Million USD | 27.141% |
| Agenus Inc. | -159.54 Million USD | 34.999% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | -6.157% |
| Dyadic International, Inc. | -8.22 Million USD | -1160.174% |
| ImmuCell Corporation | -5.74 Million USD | -1704.238% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -8600.419% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 22.852% |
| Lantern Pharma Inc. | -17.87 Million USD | -480.107% |
| Immix Biopharma, Inc. | -16.14 Million USD | -542.515% |
| Incyte Corporation | 620.52 Million USD | 116.713% |
| IO Biotech, Inc. | -91.44 Million USD | -13.414% |
| Janux Therapeutics, Inc. | -72.97 Million USD | -42.108% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | -416.227% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | -95.212% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 19.598% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -1119.962% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | -23.59% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 72.744% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 79.436% |
| NextCure, Inc. | -67.63 Million USD | -53.332% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | -881.814% |
| Onconetix, Inc. | -36.03 Million USD | -187.804% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | -148.619% |
| Opthea Limited | -191.84 Million USD | 45.941% |
| PDS Biotechnology Corporation | -43.04 Million USD | -140.93% |
| PureTech Health plc | -146.19 Million USD | 29.063% |
| Pyxis Oncology, Inc. | -82.19 Million USD | -26.173% |
| Seer, Inc. | -103.46 Million USD | -0.238% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -804161.206% |
| Clearside Biomedical, Inc. | -24.84 Million USD | -317.441% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -2530.841% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -254.464% |
| Wave Life Sciences Ltd. | -67.99 Million USD | -52.522% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | -135.649% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 25.406% |
| ChromaDex Corporation | -5.59 Million USD | -1752.277% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -1403.465% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 10.641% |
| CRISPR Therapeutics AG | -222.53 Million USD | 53.397% |
| Precision BioSciences, Inc. | -43.73 Million USD | -137.125% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 45.563% |
| Innoviva, Inc. | 176.7 Million USD | 158.689% |
| Summit Therapeutics Inc. | -89.73 Million USD | -15.571% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | -57.711% |
| Aadi Bioscience, Inc. | -71.93 Million USD | -44.174% |
| ESSA Pharma Inc. | -32.13 Million USD | -222.738% |
| GlycoMimetics, Inc. | -39.27 Million USD | -164.057% |
| GT Biopharma, Inc. | -13.57 Million USD | -663.914% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 52.692% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 219.464% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | -101.353% |
| Alzamend Neuro, Inc. | -9.93 Million USD | -943.597% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 60.06% |
| Aptose Biosciences Inc. | -52.35 Million USD | -98.084% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | -619.164% |
| Soligenix, Inc. | -7.69 Million USD | -1247.231% |
| Century Therapeutics, Inc. | -146.54 Million USD | 29.231% |
| Kura Oncology, Inc. | -165.8 Million USD | 37.451% |
| TScan Therapeutics, Inc. | -93.45 Million USD | -10.969% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | -1146.652% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -4079.053% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | -1499.46% |
| Autolus Therapeutics plc | -195.02 Million USD | 46.824% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | -22.505% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | -40.79% |
| Eterna Therapeutics Inc. | -21.13 Million USD | -390.698% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 54.32% |
| GRI Bio, Inc. | -11.38 Million USD | -810.767% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -2196.624% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 20.949% |
| IGM Biosciences, Inc. | -263.46 Million USD | 60.636% |
| INmune Bio, Inc. | -29.74 Million USD | -248.707% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 6.243% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -172.379% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -549.018% |
| Entero Therapeutics, Inc. | -15.77 Million USD | -557.6% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | -69.742% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 3.546% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 62.425% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 48.962% |
| Verastem, Inc. | -92.08 Million USD | -12.624% |
| Abeona Therapeutics Inc. | -47.13 Million USD | -120.025% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 43.681% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 12.393% |
| Histogen Inc. | -10.64 Million USD | -874.434% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | -570.303% |
| Surrozen, Inc. | -45.78 Million USD | -126.538% |
| Organovo Holdings, Inc. | -15.08 Million USD | -587.452% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -1937.41% |
| Ovid Therapeutics Inc. | -59.28 Million USD | -74.943% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -102.185% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | -310.241% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | -1258.72% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 39.452% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | -114.063% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | -32.612% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | -581.365% |
| Apollomics, Inc. | -54.83 Million USD | -89.133% |
| Amarin Corporation plc | -67.58 Million USD | -53.443% |
| Mesoblast Limited | -58.79 Million USD | -76.394% |
| Turnstone Biologics Corp. | -59.03 Million USD | -75.683% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 37.347% |
| Synaptogenix, Inc. | -8.31 Million USD | -1147.424% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | -611.017% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | -13.107% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -2064.452% |
| Monopar Therapeutics Inc. | -8.83 Million USD | -1074.343% |
| Exelixis, Inc. | 170.88 Million USD | 160.689% |
| Better Therapeutics, Inc. | -38.26 Million USD | -171.05% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 33.118% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 79.945% |
| NLS Pharmaceutics AG | -11.8 Million USD | -778.364% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | -1189.607% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -245.777% |
| Gritstone bio, Inc. | -154.63 Million USD | 32.933% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | -50.606% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | -505.669% |
| Avid Bioservices, Inc. | -18.67 Million USD | -455.247% |
| Insmed Incorporated | -709.62 Million USD | 85.385% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | -560.997% |
| MediWound Ltd. | -15.29 Million USD | -578.28% |
| OmniAb, Inc. | -69.41 Million USD | -49.396% |
| Alector, Inc. | -151.74 Million USD | 31.653% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 3.958% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -98.874% |
| Zai Lab Limited | -366.57 Million USD | 71.709% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 67.261% |
| Aura Biosciences, Inc. | -84.99 Million USD | -22.024% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 57.756% |
| Immunic, Inc. | -99.22 Million USD | -4.521% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 27.556% |
| Veracyte, Inc. | -85.79 Million USD | -20.88% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 63.2% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -629.831% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | -1405.659% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | -451.86% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 117.925% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | -307.453% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 367.277% |
| TG Therapeutics, Inc. | 20.63 Million USD | 602.637% |
| Galecto, Inc. | -39.9 Million USD | -159.89% |
| Calithera Biosciences, Inc. | -42.07 Million USD | -146.492% |
| Fortrea Holdings Inc. | 63.1 Million USD | 264.357% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 26.157% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | -259.128% |
| XBiotech Inc. | -37.51 Million USD | -176.484% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | -50.606% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | -54.513% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 3.889% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -303.977% |
| Theravance Biopharma, Inc. | -53.29 Million USD | -94.605% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 81.78% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | -32.127% |
| Vaxxinity, Inc. | -58.28 Million USD | -77.934% |
| Gain Therapeutics, Inc. | -22.25 Million USD | -366.042% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | -20.011% |
| NexImmune, Inc. | -29.19 Million USD | -255.259% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | -1745.313% |
| Marker Therapeutics, Inc. | -14.58 Million USD | -611.243% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 102.563% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | -307.357% |
| Scopus BioPharma Inc. | -11.71 Million USD | -785.276% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 18.379% |
| Ainos, Inc. | -13.2 Million USD | -685.294% |
| Pluri Inc. | -22.15 Million USD | -368.043% |
| Prothena Corporation plc | -191.03 Million USD | 45.712% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 24.869% |
| Celularity Inc. | -192.28 Million USD | 46.066% |
| Rallybio Corporation | -78.93 Million USD | -31.39% |
| Cue Biopharma, Inc. | -52.14 Million USD | -98.871% |
| MeiraGTx Holdings plc | -137.06 Million USD | 24.334% |
| Omeros Corporation | -164.53 Million USD | 36.967% |
| Humacyte, Inc. | -100.04 Million USD | -3.66% |
| Immunocore Holdings plc | -59.64 Million USD | -73.865% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | -458.807% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | -323.596% |
| Blueprint Medicines Corporation | -486.27 Million USD | 78.673% |
| CalciMedica, Inc. | -21.87 Million USD | -374.098% |
| Cabaletta Bio, Inc. | -74.66 Million USD | -38.908% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 21.125% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 39.456% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 68.275% |
| Pulmatrix, Inc. | -14.74 Million USD | -603.589% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | -190.136% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | -16.703% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 79.874% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | -53.527% |
| Cytokinetics, Incorporated | -496.2 Million USD | 79.1% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -201.313% |
| Nutriband Inc. | -4.87 Million USD | -2028.706% |
| Protara Therapeutics, Inc. | -43.61 Million USD | -137.794% |
| Vor Biopharma Inc. | -126.03 Million USD | 17.715% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 102.445% |
| Evogene Ltd. | -26.39 Million USD | -292.971% |
| ProKidney Corp. | -151.52 Million USD | 31.555% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -60.702% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | -1248.229% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 82.925% |
| CorMedix Inc. | -48.95 Million USD | -111.834% |
| BioLineRx Ltd. | -49.69 Million USD | -108.695% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 9.165% |
| Galectin Therapeutics Inc. | -38.07 Million USD | -172.402% |
| Atai Life Sciences N.V. | -125.47 Million USD | 17.344% |
| Renovaro Biosciences Inc. | -81.63 Million USD | -27.033% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | -27.393% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 58.348% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -237.375% |
| MediciNova, Inc. | -9.9 Million USD | -947.538% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 17.934% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -1331.958% |
| GeoVax Labs, Inc. | -26.74 Million USD | -287.8% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 55.264% |
| Biomea Fusion, Inc. | -126.13 Million USD | 17.779% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 70.318% |
| Mereo BioPharma Group plc | -28.41 Million USD | -264.967% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 45.727% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 54.9% |
| Absci Corporation | -115.51 Million USD | 10.22% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -275.934% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 8.114% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 57.174% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | -311.609% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 50.138% |
| Allakos Inc. | -196.05 Million USD | 47.102% |
| Imunon, Inc. | -21.03 Million USD | -393.138% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 6.285% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 196.67% |
| BioAtla, Inc. | -129.68 Million USD | 20.031% |
| NLS Pharmaceutics AG | -11.8 Million USD | -778.364% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -554.605% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 68.356% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | -148.357% |
| XOMA Corporation | -41.84 Million USD | -147.823% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 1.452% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 14.639% |
| aTyr Pharma, Inc. | -54.91 Million USD | -88.84% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | -18.624% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 40.008% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 59.242% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | -383.131% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | -1162.78% |
| Akari Therapeutics, Plc | -16.8 Million USD | -517.095% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -1172676.752% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 130.722% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -1487.215% |
| UroGen Pharma Ltd. | -65.53 Million USD | -58.247% |
| Sutro Biopharma, Inc. | -89.27 Million USD | -16.164% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -1327.906% |
| Orgenesis Inc. | -53.63 Million USD | -93.357% |
| Entera Bio Ltd. | -8.89 Million USD | -1066.449% |
| GH Research PLC | -41.22 Million USD | -151.587% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | -303.411% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | -24.871% |
| Xencor, Inc. | -138.63 Million USD | 25.195% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | -1911.977% |
| Replimune Group, Inc. | -234.77 Million USD | 55.826% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | -382.567% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | -643.327% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -1487.215% |
| Portage Biotech Inc. | -18.25 Million USD | -468.175% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -1331.958% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 1.193% |
| OncoCyte Corporation | -25.13 Million USD | -312.592% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -817.384% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -805.197% |
| Purple Biotech Ltd. | 22.27 Million USD | 565.668% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | -1280.578% |
| scPharmaceuticals Inc. | -55.39 Million USD | -87.214% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | -448.792% |
| HilleVax, Inc. | -133.34 Million USD | 22.225% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | -760.727% |
| Tharimmune, Inc. | -9.45 Million USD | -996.844% |
| Genprex, Inc. | -31.07 Million USD | -233.732% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 44.893% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | -230.526% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -13456.732% |
| Virios Therapeutics, Inc. | -5.44 Million USD | -1803.994% |
| OKYO Pharma Limited | -15.74 Thousand USD | -658381.13% |
| Savara Inc. | -60 Million USD | -72.828% |
| Curis, Inc. | -48.33 Million USD | -114.576% |
| Daré Bioscience, Inc. | -30.83 Million USD | -236.282% |
| Carmell Therapeutics Corporation | -5.21 Million USD | -1887.798% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | -1325.161% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | -280.583% |
| BeiGene, Ltd. | -1.2 Billion USD | 91.413% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -420.124% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 78.713% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | -10.739% |
| Erasca, Inc. | -141.52 Million USD | 26.72% |
| bluebird bio, Inc. | -244.26 Million USD | 57.542% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -2190.912% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 153.337% |
| DBV Technologies S.A. | -76.43 Million USD | -35.688% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -2190.912% |
| Moderna, Inc. | -4.23 Billion USD | 97.553% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -143.397% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | -1530.645% |
| Molecular Templates, Inc. | -10.46 Million USD | -890.913% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | -54.244% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 72.472% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 27.634% |
| Spruce Biosciences, Inc. | -51.99 Million USD | -99.467% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 32.893% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 50.171% |
| MacroGenics, Inc. | -168.24 Million USD | 38.358% |
| RenovoRx, Inc. | -11.39 Million USD | -810.047% |
| Adicet Bio, Inc. | -152.03 Million USD | 31.787% |
| Prime Medicine, Inc. | -191.29 Million USD | 45.785% |
| Aditxt, Inc. | -26.06 Million USD | -297.925% |
| Adagene Inc. | -23.71 Million USD | -337.224% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1318.709% |
| Quantum-Si incorporated | -111.17 Million USD | 6.712% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | -227.695% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | -611.419% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 184.998% |
| SciSparc Ltd. | -5.77 Million USD | -1696.449% |
| Vericel Corporation | -6.46 Million USD | -1504.409% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -1098.025% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | -348.577% |
| Generation Bio Co. | -138.56 Million USD | 25.154% |
| Astria Therapeutics, Inc. | -83.03 Million USD | -24.905% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | -19.95% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 56.985% |
| Invivyd, Inc. | -207.78 Million USD | 50.088% |
| Relay Therapeutics, Inc. | -373 Million USD | 72.196% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | -1005.816% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 582.794% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -908.156% |
| 2seventy bio, Inc. | -216.7 Million USD | 52.142% |
| ADMA Biologics, Inc. | 21.63 Million USD | 579.424% |
| Clene Inc. | -40.54 Million USD | -155.819% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | -330.724% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | -89.264% |
| GeoVax Labs, Inc. | -26.74 Million USD | -287.8% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 70.374% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | -182.34% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 745.077% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | -0.007% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -205.009% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 39.094% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 84.845% |
| Evaxion Biotech A/S | -22.19 Million USD | -367.221% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | -25.888% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 53.52% |
| Trevena, Inc. | -35.28 Million USD | -193.893% |
| Surrozen, Inc. | -45.78 Million USD | -126.538% |
| Tyra Biosciences, Inc. | -79.94 Million USD | -29.725% |
| Cingulate Inc. | -22.75 Million USD | -355.68% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 1484.263% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -132.183% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | -1159.531% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | -1.122% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | -41.333% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | -67.073% |
| Clearmind Medicine Inc. | -8.74 Million USD | -1086.419% |
| Kronos Bio, Inc. | -121.83 Million USD | 14.874% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | -36.108% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -3435.954% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -2.858% |
| Statera Biopharma, Inc. | -98.34 Million USD | -5.456% |
| ImmunityBio, Inc. | -362.25 Million USD | 71.371% |
| Korro Bio, Inc. | -84.53 Million USD | -22.683% |
| Kineta, Inc. | -15.72 Million USD | -559.601% |
| BioVie Inc. | -32.17 Million USD | -222.282% |
| Codexis, Inc. | -68.06 Million USD | -52.359% |
| Celularity Inc. | -192.28 Million USD | 46.066% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 53.412% |
| Celcuity Inc. | -66.23 Million USD | -56.588% |
| Virax Biolabs Group Limited | -6.49 Million USD | -1496.389% |
| Cibus, Inc. | -318.88 Million USD | 67.477% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | -141.184% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -206.432% |
| IN8bio, Inc. | -30.33 Million USD | -241.856% |
| Kodiak Sciences Inc. | -277.32 Million USD | 62.603% |
| Annexon, Inc. | -143.72 Million USD | 27.841% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 16.223% |
| Assembly Biosciences, Inc. | -64.64 Million USD | -60.426% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | -342.369% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 70.681% |
| Eyenovia, Inc. | -25.4 Million USD | -308.2% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 417.736% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -1764.599% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | -31.057% |
| Arcellx, Inc. | -89.88 Million USD | -15.386% |
| Cardiff Oncology, Inc. | -45.41 Million USD | -128.374% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 24.414% |
| Regulus Therapeutics Inc. | -31.1 Million USD | -233.373% |
| Moolec Science SA | -6.65 Million USD | -1458.642% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | -69.631% |
| Geron Corporation | -193.94 Million USD | 46.526% |
| LAVA Therapeutics N.V. | -43.25 Million USD | -139.773% |
| Royalty Pharma plc | 1.49 Billion USD | 106.95% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 36.825% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -1011.819% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | -373.673% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 39.336% |
| Humacyte, Inc. | -100.04 Million USD | -3.66% |
| Structure Therapeutics Inc. | -102.77 Million USD | -0.909% |
| 89bio, Inc. | -151.2 Million USD | 31.411% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | -29.423% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | -613.267% |
| Genelux Corporation | -24.16 Million USD | -329.17% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | -205.719% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 39.616% |
| Notable Labs, Ltd. | -14.65 Million USD | -607.573% |
| Liquidia Corporation | -73.38 Million USD | -41.324% |
| Mustang Bio, Inc. | -50.72 Million USD | -104.449% |
| Immunovant, Inc. | -282.7 Million USD | 63.316% |
| Quantum-Si incorporated | -111.17 Million USD | 6.712% |
| Arbutus Biopharma Corporation | -78.1 Million USD | -32.785% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | -387.652% |
| Vera Therapeutics, Inc. | -102.01 Million USD | -1.664% |
| Acasti Pharma Inc. | -11.31 Million USD | -816.805% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | -352.461% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -549.018% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 51.55% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -2726.573% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -552.833% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | -255.692% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | -150.602% |
| PepGen Inc. | -84.76 Million USD | -22.347% |
| Moleculin Biotech, Inc. | -29.63 Million USD | -250.002% |
| United Therapeutics Corporation | 1.18 Billion USD | 108.753% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -352.937% |
| Solid Biosciences Inc. | -104.31 Million USD | 0.581% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | -216.108% |
| Immuneering Corporation | -58.41 Million USD | -77.545% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -1937.41% |
| Silo Pharma, Inc. | -3.85 Million USD | -2589.833% |
| Belite Bio, Inc | -31.66 Million USD | -227.488% |
| XOMA Corporation | -41.84 Million USD | -147.823% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | -53.597% |
| Bionomics Limited | -17.89 Billion USD | 99.42% |
| Apogee Therapeutics, Inc. | -93 Million USD | -11.511% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 390.664% |
| uniQure N.V. | -282.87 Million USD | 63.337% |
| Cassava Sciences, Inc. | -105.95 Million USD | 2.122% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1318.709% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 19.918% |
| Forte Biosciences, Inc. | -32.48 Million USD | -219.242% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | -1148.189% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | -252.812% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -1764.599% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -629.831% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | -1066.712% |
| Altimmune, Inc. | -95.92 Million USD | -8.11% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -41.112% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 390.664% |
| Compugen Ltd. | -12.99 Million USD | -698.253% |
| Peak Bio, Inc. | -1356.23 USD | -7646759.309% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | -109.074% |
| Benitec Biopharma Inc. | -22.49 Million USD | -361.134% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 57.199% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | -248.649% |
| Zura Bio Limited | -62.63 Million USD | -65.569% |
| PolyPid Ltd. | -22.86 Million USD | -353.531% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | -537.19% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | -248.649% |
| Instil Bio, Inc. | -159.16 Million USD | 34.843% |
| argenx SE | -425.04 Million USD | 75.601% |
| Immunome, Inc. | -109.53 Million USD | 5.315% |
| Compass Therapeutics, Inc. | -50.36 Million USD | -105.923% |
| Verona Pharma plc | -67.83 Million USD | -52.893% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | -297.962% |
| Shattuck Labs, Inc. | -91.95 Million USD | -12.78% |
| CervoMed Inc. | -7.81 Million USD | -1227.408% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | -41.853% |
| Plus Therapeutics, Inc. | -13.32 Million USD | -678.538% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -115.28% |
| Moolec Science SA | -6.65 Million USD | -1458.642% |
| Enveric Biosciences, Inc. | -16.44 Million USD | -530.51% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 23.307% |
| AnaptysBio, Inc. | -164.41 Million USD | 36.921% |
| Design Therapeutics, Inc. | -78.19 Million USD | -32.637% |
| Leap Therapeutics, Inc. | -87.04 Million USD | -19.15% |
| NeurAxis, Inc. | -6.66 Million USD | -1456.142% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | -156.078% |
| Lumos Pharma, Inc. | -36.61 Million USD | -183.25% |
| Achilles Therapeutics plc | -75.25 Million USD | -37.81% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | -297.962% |
| 180 Life Sciences Corp. | -13.47 Million USD | -669.497% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 2111.302% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -3435.954% |
| Nutriband Inc. | -4.87 Million USD | -2028.706% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 6.383% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | -87.035% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | -104.007% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | -56.899% |
| MoonLake Immunotherapeutics | -54.12 Million USD | -91.617% |
| Palisade Bio, Inc. | -13.07 Million USD | -693.489% |
| Tourmaline Bio, Inc. | -45.4 Million USD | -128.389% |
| Beam Therapeutics Inc. | -176.48 Million USD | 41.236% |
| Neurogene Inc. | -55.58 Million USD | -86.584% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 4.988% |
| AEON Biopharma, Inc. | -48.42 Million USD | -114.146% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | -7.237% |
| Sesen Bio, Inc. | -25.9 Million USD | -300.282% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | -24.159% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | -723.944% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 77.482% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | -43.167% |
| Athira Pharma, Inc. | -125.46 Million USD | 17.341% |
| Vaccinex, Inc. | -22.88 Million USD | -353.175% |
| HCW Biologics Inc. | -25.71 Million USD | -303.268% |
| XOMA Corporation | -41.84 Million USD | -147.823% |
| Nektar Therapeutics | -137.42 Million USD | 24.534% |
| Arvinas, Inc. | -401.5 Million USD | 74.17% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -1172676.752% |
| Merus N.V. | -156.54 Million USD | 33.752% |
| Omega Therapeutics, Inc. | -100.26 Million USD | -3.439% |
| Quince Therapeutics, Inc. | -34.62 Million USD | -199.564% |
| Rezolute, Inc. | -70.42 Million USD | -47.266% |
| Clene Inc. | -40.54 Million USD | -155.819% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | -533.203% |
| BeyondSpring Inc. | -23.11 Million USD | -348.685% |
| Synlogic, Inc. | -55.16 Million USD | -88.011% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | -478.443% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -858.139% |
| Peak Bio, Inc. | -1356.23 USD | -7646759.309% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | -156.053% |
| Krystal Biotech, Inc. | -109.72 Million USD | 5.485% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 19.941% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 69.765% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -2085.209% |
| MannKind Corporation | 8.67 Million USD | 1295.08% |
| Ikena Oncology, Inc. | -75.41 Million USD | -37.514% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | -975.039% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | -54.26% |
| Gossamer Bio, Inc. | -183.75 Million USD | 43.562% |
| CohBar, Inc. | -12.38 Million USD | -737.153% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | -104.457% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -275.934% |
| Legend Biotech Corporation | -439.48 Million USD | 76.402% |
| Mural Oncology plc | -194.63 Million USD | 46.717% |
| Biora Therapeutics, Inc. | -67.14 Million USD | -54.46% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -542.349% |
| Disc Medicine, Inc. | -91.12 Million USD | -13.81% |
| Champions Oncology, Inc. | -7.35 Million USD | -1309.856% |
| REGENXBIO Inc. | -268.12 Million USD | 61.321% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -867.598% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -86.005% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | -166.189% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 9.311% |
| Vaxart, Inc. | -83.34 Million USD | -24.43% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | -1117.241% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | -142.344% |
| Cellectis S.A. | -106.62 Million USD | 2.736% |
| Longeveron Inc. | -21.02 Million USD | -393.171% |
| Repare Therapeutics Inc. | -116.22 Million USD | 10.768% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 61.277% |
| Inozyme Pharma, Inc. | -75.64 Million USD | -37.1% |
| Revolution Medicines, Inc. | -487.18 Million USD | 78.713% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | -1459.065% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | -135.949% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | -39.039% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | -48.932% |
| Anixa Biosciences, Inc. | -11.01 Million USD | -841.867% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 102.408% |
| Denali Therapeutics Inc. | -196.69 Million USD | 47.275% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -1098.025% |
| Veru Inc. | -93.78 Million USD | -10.585% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | -344.55% |
| Cingulate Inc. | -22.75 Million USD | -355.68% |
| Passage Bio, Inc. | -108.38 Million USD | 4.318% |
| Context Therapeutics Inc. | -25.07 Million USD | -313.635% |
| Exicure, Inc. | -14.99 Million USD | -591.578% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 49.671% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | -155.453% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | -967.301% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 43.746% |
| Nuvalent, Inc. | -149.49 Million USD | 30.626% |
| ABVC BioPharma, Inc. | -8.21 Million USD | -1162.203% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | -16.88% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | -399.225% |
| OmniAb, Inc. | -69.41 Million USD | -49.396% |
| Anew Medical, Inc. | -1.3 Million USD | -7872.464% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | -712.066% |
| Lipocine Inc. | -17.93 Million USD | -478.38% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | -51.371% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | -36.187% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -172.379% |
| G1 Therapeutics, Inc. | -39.52 Million USD | -162.375% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | -363.318% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 82.114% |
| Ocugen, Inc. | -65.53 Million USD | -58.259% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | -10.486% |
| Q32 Bio Inc. | -92.1 Million USD | -12.602% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | -383.74% |
| Alumis Inc. Common Stock | -158.17 Million USD | 34.434% |
| Equillium, Inc. | -14.52 Million USD | -614.151% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | -66.184% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -1212.216% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -449.74% |
| Galera Therapeutics, Inc. | -46.95 Million USD | -120.888% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 4.386% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -766.407% |
| Dominari Holdings Inc. | -21.79 Million USD | -375.817% |
| Edesa Biotech, Inc. | -9.22 Million USD | -1024.49% |
| vTv Therapeutics Inc. | -25.5 Million USD | -306.67% |
| Bio-Techne Corporation | 206.68 Million USD | 150.177% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 73.509% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 154.007% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 21.597% |
| Candel Therapeutics, Inc. | -38.39 Million USD | -170.139% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 31.364% |
| Nkarta, Inc. | -131.65 Million USD | 21.224% |
| BioCardia, Inc. | -11.64 Million USD | -790.665% |
| Iterum Therapeutics plc | -47.46 Million USD | -118.482% |